EVAC
_________________________________________________________________
  etoposide....... 150 mg/sqm IV on days 1 and 8.
  vincristine..... 1 mg/sqm IV on days 1 and 8 (day 8 deleted 
                   after 3 cycles).
  adriamycin...... 40 mg/sqm IV day 1.
  cytoxan......... 200 mg/sqm orally on days 3, 4, 5 and 6.
  FREQUENCY....... Repeat cycle every 21 days.


  reference...
    Goodman GE.  Miller TP.  Manning MM.  Davis SL.  McMahon LJ. 
    Treatment of small cell lung cancer with VP-16, vincristine, 
    doxorubicin (Adriamycin), cyclophosphamide (EVAC), and 
    high-dose chest radiotherapy. Journal of Clinical Oncology.  
    1(8):483-8, 1983 Aug. 
  abstract...
    Seventy-one previously untreated patients with small cell lung 
    cancer (SCLC) received a combination of VP-16, vincristine, 
    doxorubicin (Adriamycin), and cyclophosphamide (EVAC) repeated 
    every three weeks. Limited-disease (LD) patients and 
    extensive-disease (ED) patients achieving a complete response 
    (CR) or partial response (PR) after four to six cycles of EVAC 
    received 4,000 rads over four weeks whole-brain radiotherapy 
    (RT) and 5,000 rads over five weeks RT to the original 
    pulmonary primary and mediastinum. ED patients with persisting 
    disease outside the chest after six cycles of EVAC continued 
    chemotherapy and did not receive RT. After RT was completed, 
    EVAC was continued for a total treatment duration of 24 
    months. Of 65 patients evaluable for response 76% (25 of 33) 
    of LD patients and 34% (11 of 32) of ED patients achieved a CR 
    prior to RT; two additional ED patients achieved a CR after 
    RT. Median survival for all 71 patients was 48 weeks (range, 
    one to 207 weeks); median survival for 33 LD patients was 92 
    weeks and for 38 ED patients it was 36 weeks. Nine of 25 LD 
    patients and 10 of 13 ED patients have relapsed from CR. The 
    EVAC-RT protocol is promising in view of the high CR rate and 
    long remission duration achieved, especially among patients 
    with LD.